GlassScriptPhysician profile
Neeta Vorst
NPI 1801399555
$17,619.88
in general payments reported to CMS, 2019-2025
40 companies · $3,333 in 2025
The $3,333 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,870 · 2022: $4,216 · 2023: $4,581 · 2024: $2,619 · 2025: $3,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,945 · Education: $589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,944.56 |
| Education | $588.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,088.71 | 2021-2025 | Fasenra, Breztri, Tezspire |
| Genzyme Corporation | $1,559.75 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,374.55 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,191.89 | 2021-2025 | Ofev, Jascayd, Spiriva Respimat |
| United Therapeutics Corporation | $1,190.76 | 2021-2025 | Tyvaso, Tyvaso, Orenitram |
| Mallinckrodt Hospital Products INC. | $1,167.80 | 2021-2025 | Acthar, Terlivaz |
| Actelion Pharmaceuticals US, INC. | $995.64 | 2021-2025 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $829.97 | 2021-2025 | Dupixent |
| Mylan Specialty L.P. | $792.64 | 2021-2024 | Yupelri |
| Ani Pharmaceuticals, INC. | $641.21 | 2022-2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $504.74 | 2021-2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $440.55 | 2021-2025 | Glassia |
| Amgen INC. | $439.12 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $347.57 | 2021-2025 | |
| Insmed, INC. | $333.48 | 2021-2025 | Arikayce, Brinsupri |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $307.19 | 2021-2023 | Airduo Digihaler |
| Pulmonx Corporation | $253.30 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| La Jolla Pharmaceutical Company | $247.36 | 2021-2025 | Giapreza |
| Grifols USA, LLC | $238.26 | 2022-2024 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $189.85 | 2021-2025 | |
| Inogen, INC. | $189.16 | 2022-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Janssen Pharmaceuticals, INC | $189.15 | 2021-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $151.79 | 2022-2025 | |
| Baxter Healthcare | $134.53 | 2022-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care |
| Electromed, INC. | $132.00 | 2021-2025 | Smartvest |
| Philips North America LLC | $131.01 | 2021-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Vifor Pharma, INC. | $75.91 | 2024-2025 | Veltassa, Zemaira |
| Advanced Respiratory, INC | $71.07 | 2021 | |
| Viatris Specialty LLC | $62.07 | 2025 | Yupelri |
| Verona Pharma, INC. | $56.20 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $40.56 | 2024 | Inspire |
| Merck Sharp & Dohme LLC | $39.61 | 2022-2025 | Zerbaxa |
| E.R. Squibb & Sons, L.L.C. | $39.58 | 2021 | |
| Pharming Healthcare, INC. | $36.69 | 2023 | Ruconest |
| Acacia Pharma INC | $33.58 | 2021-2022 | |
| Harmony Biosciences LLC | $25.18 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.50 | 2022 | |
| Ethicon INC. | $21.98 | 2021 | |
| Gilead Sciences, INC. | $18.94 | 2023 | |
| Pfizer INC. | $14.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neeta Vorst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.